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ABSTRACT 
Objective: The purpose of this study was to design and formulate mucoadhesive buccal patches of sodium cromoglycate (SCG) as an alternative way 
to overcome its poor oral absorption and short half-life.  
Methods: Mucoadhesive patches were prepared by solvent casting technique using cellulose acetate butyrate (CAB) alone or in combination with 
mucoadhesive polymers like SCMC (sodium carboxymethyl cellulose), HPMC 100M (hydroxyl propyl methyl cellulose) and Cbp934P (carbopol) in different 
concentrations. The successful patches were evaluated for thickness, weight variation, folding endurance, tensile strength, drug content, surface pH, moisture 
uptake, swelling percentage, mucoadhesion strength, residence time, in vitro release study, ex vivo permeation and in vivo pharmacokinetic studies. 
Results: The thickness of all prepared patches ranged from 0.210±0.006 to0.355±0.012, folding endurance was more than 300, weight variation did 
not exceed 0.179±0.015, tensile strength and % elongation ranged from 6.4±0.018 to 13.1±0.024, and from 30.4±0.88 to 53.4±0.78respectively. The 
swelling percentage after one hour was from 20.8±0.99 to 53.2±1.5. pH of all prepared patches did not exceed 6.8, the drug content was about 99 to 
101%, moisture uptake did not exceed 10%. Mucoadhesion strength and residence time ranged from 17.2±0.14 to 51.2±0.26, and from 3.35±0.25 to 
7.45±0.28 respectively. The cumulative release percentage of SCG was in the following descending order CAB>CAB with Cbp934P>CAB with 
HPMC>CAB with SCMC. The optimized patch (F9) decreased the Cmax and increased Tmax compared to the parenteral solution. 
Conclusion: It can be concluded that mucoadhesive buccal patch is a promising dosage form to prolong the release of SCG and enhance its poor oral 
bioavailability. 
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Although oral drug delivery remains the most common and 
preferred route for delivery of many drugs, it suffers from several 
important drawbacks such as enzymatic degradation along the 
gastrointestinal tract, first pass metabolism, delayed onset of 
absorption and sometimes poor absorption. These defects 
necessitate the importance of designing alternative dosage forms to 
be administered through alternative routes such as pulmonary, 
transdermal, ocular, rectal, vaginal and buccal. The buccal route 
overcomes the disadvantages associated with the oral route for 
systemic drug delivery [1, 2]. These include avoidance of first-pass 
metabolism and enzymatic degradation, rapid onset of absorption, 
prolonged release of certain drugs and ease administration of drugs 
[3]. Buccal patches suffer from certain limitations which include [4]: 
certain drugs which have undesirable taste, irritate buccal mucosa, 
unstable in buccal pH, discolor the teeth and drugs with large dose 
could not be formulated as buccal patches. Mucoadhesive buccal 
patches are more recent dosage form which is designed to give 
systemic or local drug delivery and fabricated to overcome the short 
residence time of oral gel which is easily washed by saliva [5] and 
discomfort of solid dosage forms like tablets. Sodium cromoglycate 
is a mast cell stabilizer that inhibits the release of inflammatory 
mediators and prevents the immediate onset and delayed onset 
asthma [6, 7]. It suffers from poor oral absorption, which is found to 
be 0.5% of the total administered dose and short plasma half-life 
which is 60-90 min [8]. This research work aims to design, formulate 
and evaluate mucoadhesive buccal patches of SCG to overcome its 
poor oral absorption and prolonged its release and consequently 
enhances its bioavailability.  
MATERIALS AND METHODS 
Materials  
Sodium cromoglycate was kindly supplied by sigma company, Egypt. 
Phosphoric acid and Potassium-dihydrogen phosphate were 
purchased from El Nasr Company Egypt. HPLC grade acetonitrile, 
SCMC, Cbp934 P and HPMC100M were purchased from Sigma-Aldrich 
Chemie, Germany. All other chemicals and solvents are of analytical 
grade. Diethyl ether was purchased from Fine Chem. Ltd. (India). 
Methods  
Preparation of mucoadhesive buccal patches 
The solvent casting technique was used for the preparation of SCG 
mucoadhesive patch [9-12]. The composition of the successful 
patches was illustrated in table 1. The calculated amount of the drug 
and polyethyleneglycol 600 as a plasticizer (50% W/W of dry 
polymer weight) were dissolved in a 20 ml mixture of absolute 
ethanol and methylene chloride (1:1) as casting solvent. The 
calculated amount of the polymer or polymer mixture was sprinkled 
onto the solution with occasional shaking. The casting solution was 
then adjusted to 25 ml to give 4% W/V polymeric solution and left 
for 24 h for complete dissolution and removal of suspended air 
bubbles. The solution was then cast in a glass petri dish (area=50.24 
cm2) covered with inverted glass funnel to control the rate of 
evaporation and prevent patch blistering. The solvent was allowed 
to evaporate for 24 h at ambient room temperature. The dry patch 
was isolated and cut into square sections of 2x2 cm, each containing 
20 mg of SCG and finally wrapped in an aluminium foil and stored in 
a desiccator. 
Evaluation of mucoadhesive buccal patches 
Physical appearance 
All prepared buccal patches were visually inspected for clarity, 
smoothness and flexibility. 
Thickness 
The thickness of three patches of each formulation was measured 
with a digital micrometre (Cole-Parmer Instrumental Co., Japan) at 
five different places and the mean thickness was determined [13]. 
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Table 1: Composition of successful sodium cromoglycate buccal mucoadhesive patches 
Formula code SCG (mg) CAB (mg) Cbp934p (mg) CMCS (mg) HPMC100M (mg) 
F1 20 1000    
F2 20 800 200 ---- ---- 
F3 20 700 300 ---- ---- 
F4 20 600 400 ---- ---- 
F5 20 500 500 ---- ---- 
F6 20 800 ---- 200 ---- 
F7 20 700 ---- 300 ---- 
F8 20 600 ---- 400 ---- 
F9 20 500 ---- 500 ---- 
F10 20 800 ---- ---- 200 
F11 20 700 ---- ---- 300 
F12 20 600 ---- ---- 400 
F13 20 500 ---- ---- 500 
SCG: sodium cromoglycate, CAB: cellulose acetate butyrate, Cbp934p: carbopol934p, SCMC: sodium carboxymethyl cellulose, HPMC100M: hydroxyl 
propyl methyl cellulose 
 
Weight variation 
All prepared patches were subjected to weight variation test by 
individually weighing three randomly selected patches (2x2 cm) for 
each formula [14] using an electronic digital balance (Metter-Toledo, 
Ag, CH 8606, Greifensee, Switzerland). 
Tensile strength and percent elongation 
Tensile strength and percent elongation were determined using JJ 
load cell instrument 100n, j. j LIoyd instruments limited (warash, 
Southampton, England). The dried piece of each patch with uniform 
size 8x100 mm was clamped using an upper and lower flat faced 
metal grip. The distance between the grips and the effective length of 
the patch under stress was kept constant at 40 mm. A crosshead 
speed of 3 mm/min was started. When the film broke, the force and 
elongation were measured [15, 16]. The average of three 
measurements for each formula was determined. Tensile strength 
can be calculated according to the following equation:  
Tensile strength=
breaking load
cross sectional area 
 








SCG patch of each formula (2x2 cm) was soaked for 1 h in 5 ml 
distilled water at ambient room temperature. pH was determined by 
mounting the electrode of pH meter300 (Jenway LTD, UK) on the 
patch surface and permitting equilibration for 1 min. The 
experiment was conducted in triplicate [17]. 
Drug content uniformity 
SCG patch 2x2 cm of each formula was dissolved in 100 ml phosphate 
buffer pH 6.8 with occasional stirring and then filtered. SCG was 
determined spectrophotometrically at 326 nm using UV-Spectro-
photometer Shimadzu UV-1201, Japan against phosphate buffer pH 6.8 
as a blank. The experiment was performed in triplicate [18]. 
Folding endurance 
Folding endurance of each formula was conducted by folding section 
of 2x2 cm size repeatedly at the same place till it broke or folded up 
to 300 times. 
The value of folding endurance is expressed as the number of times the 
film could be folded at the same position without breaking. Folding 
endurance is given as the average of three determinations [19, 20]. 
Moisture uptake 
The patches of all prepared formulations were placed in a desiccator 
containing 200 ml saturated solution of potassium chloride to give 
relative humidity of 84% for 3 d. At the end of the experiment, the 
patches were removed and weighed [21]. The percent moisture uptake 
of each patch was calculated according to the following equation:  





Square section of each patch measuring 2x2 cm was carefully 
weighed, then immersed in 50 ml phosphate buffer pH 6.8 in a glass 
petri dish. The patch section was removed carefully at 5, 10, 15, 20, 
30 and 60 min interval, dried carefully with the aid of filter paper 
and accurately weighed [22, 23]. Swelling percentage was calculated 
according to the following equation. 
Swelling percentage = 
WtW0
W0
 x 100 
Where  
W0= the initial weight at zero time 
Wt = the weight of the swollen patch at time t.  
Swelling percentage expressed as the average of three determinations. 
Ex-vivo mucoadhesion strength 
A modified physical balance was used for the determination of 
mucoadhesion strength of the prepared patches using the porcine 
buccal mucosa. The buccal mucosa was cut carefully into pieces and 
washed with pH 6.8 phosphate buffer. A piece of the porcine buccal 
mucosa was firmly tied to the open mouth of a glass vial which was 
completely filled with pH 6.8 phosphate buffer. The glass vial was 
firmly fitted to the centre of a glass beaker which was filled with pH 
6.8 phosphate buffer kept at 37±0.5 °C to the level that just touches 
the mucosal surface. The patch was tightly stuck to the lower surface 
of the rubber stopper using cyanoacrylate adhesive. 5 g weight was 
put on right side pan for balancing the two pans. The weight was 
then removed, which lowered the pan along with the film over the 
mucosa. The balance was kept for 5 min at such position. Water then 
added slowly at a rate of 100 drops/min with the aid of the infusion 
set. The weight of water in grams that completely detached the patch 
from the surface of buccal mucosa was used in the calculation of 
mucoadhesion strength [24-26] according to the following equation:  




Where m is the weight of water in g 
gr equal 980 cm/sec2 the acceleration due to gravity  
A is the area of porcine mucosa equal to πr2 where r is the radius of 
the exposed porcine buccal mucosa. 
Ex-vivo mucoadhesion residence time 
Ex-vivo determination of mucoadhesion time was conducted using 
porcine buccal mucosa. The segment of the porcine mucosa was glued 
onto the internal side of a glass beaker using cyanoacrylate adhesive. The 
patch which was previously hydrated with pH 6.8 phosphate buffer was 
then attached to the mucosa by applying light force for 20 Sec with a 
fingertip. The beaker was then filled with 200 ml pH 6.8 phosphate 
buffer and was kept at 37±0.5 °C and 50 RPM in a thermostatic shaker 
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water bath (Julabo SW-20 C, Germany). Ex-vivo mucoadhesion time is 
the time taken by the patch to erode or dislodge from the mucosa. The 
experiment was performed in triplicate [28]. 
In vitro release study 
The cumulative drug release percent of SCG from different patches 
was conducted using USP type II dissolution apparatus paddle type. 
2x2 cm section of each formula was attached to a glass slide using 
cyanoacrylate adhesive. The glass slide was placed in the bottom of 
dissolution vessel. 500 ml pH 6.8 phosphate buffer was used as the 
release medium and maintained at 37±0.5 °C and 50 RPM. 5 ml 
sample was withdrawn at 1, 2, 3, 4, 5, 6, 7, 8 h and replaced with an 
equal volume of fresh buffer. The samples were filtered, accurately 
diluted and analyzed spectrophotometrically at 326 nm. The 
experiment was conducted in triplicate [29]. 
Ex-vivo drug permeation study. 
Franz diffusion cell was used for the permeation study. The porcine oral 
mucosa was used as the model mucosal membrane. The buccal mucosa 
was washed and stabilized in phosphate buffer pH 6.8 to remove any 
soluble component. The porcine mucosa was mounted between the 
donor and receptor compartments. 20 ml phosphate buffer pH 6.8 was 
filled into the receptor compartment maintained at 37±0.5 °C and stirred 
using magnetic bead at 50 RPM. 3 ml sample was withdrawn at a 
predetermined time interval and replaced with fresh buffer. The amount 
of SCG was estimated spectrophotometrically at 326 nm. The experiment 
was performed in triplicate [30, 31]. 
In vivo pharmacokinetic study 
SCG was estimated in rabbit plasma by simple and sensitive RP-
HPLC method described by paparajusowjanya et al. [32] with certain 
modifications. 
Experimental design 
White male albino rabbits (2-2.5 kg) were used for the 
pharmacokinetic study. Animals were housed at the standardized 
condition of the animal house of faculty of pharmacy, Zagazig 
University, Zagazig, Egypt. All animals were acclimatized and kept 
constant at ambient room temperature. All animal procedures were 
performed in accordance with the approved protocol for the use of 
experimental animals set by the standing committee on the animal 
care of the faculty of pharmacy, Zagazig University, EgyptP3-12-
2016. Animals were divided into three groups, each group of six 
rabbits. Group 1 act as a control, group 2 received the optimized 
patch F9 and group 3 received SCG solution parenterally. Group 2 
and group 3 received a dose of 5 mg/kg, which was determined by 
trials. Blood samples were withdrawn from the sinus orbital at 0.5, 
1, 2, 4, 6, 8, 10, 12, 24 h. The blood samples were centrifuged at 3000 
RPM for 10 min. SCG was extracted from rabbit plasma by adding 
100 µl of 10% perchloric acid to precipitate the protein. 1 ml rabbit 
plasma was vortexed for 1 min, then 2 ml diethyl ether was added. 
The mixture was centrifuged at 5000 RPM and 4 ° C for 10 min, then 
2 ml of the supernatant was taken and dried in a vacuum oven at 40 
° C. The residue was reconstituted with 20 µl mobile phase and 
injected into the column. 
HPLC conditions 
HPLC (Waters Instrument, Germany) with the reverse phase C18 
column. The UV detector was set at 240 nm for sample detection. The 
mobile phase consisted of acetonitrile and potassium di hydrogen ortho 
phosphate adjusted to pH 1.5 with orthophosphoric acid in the ratio of 
25:75 at a flow rate of 1 ml/min. 10 mg of SCG was dissolved in 10 ml of 
mobile phase and suitably diluted to produce a stock solution of 1 
mg/ml. Dilution of stock solution was performed to give 10, 15, 20, 25, 
30, 35 µg/ml.100 µl of spiked plasma was added to each of the above 
concentrations and the samples were analyzed as previously described. 
Kinetic data analysis 
The cumulative drug release percentages were plotted according to 
the different kinetic models such as Higuchi diffusion, zero order, 
first order, Korsmeyer-Peppas, and Hixson and Crowell to determine 
the best kinetic model of the drug release [33]. 
Statistical analysis  
The resulting data of different evaluated parameters were expressed as 
the average mean±standard deviation of the mean. One way analysis of 
variance (ANOVA) was employed for the data analysis using SPSS 
program, version 16. The data were significant at a level P<0.05. 
RESULTS AND DISCUSSION 
Physical appearance and thickness 
All prepared patches were translucent and smooth. The average 
thickness of all patches was found in the range from 0.21±0.006 to 
0.355±0.012 mm (table 2). 
Weight variation 
The weight of all prepared patches (2x2 cm) ranged from 
0.155±0.025 to 0.179±0.015 mg. The results in table 2 demonstrate 
the uniformity of weight of all prepared patches.  
Folding endurance 
The folding endurance of all prepared patches was more than 300 
irrespective to the type of the polymer which ensures flexibility and 
toughness of all prepared patches (table 2) [34]. 
Tensile strength and percent elongation 
Tensile strength and percent elongation give an indication for the 
elasticity and strength of the prepared patches. Soft and tough 
patches have the high tensile strength and percent elongation. Data 
recorded in table 2 show that the tensile strength of CAB patch (F1) 
was 6.4±0.018 and percent elongation was 30.4±0.88. The addition 
of mucoadhesive polymers increased both mechanical parameters. 
The effect of the mucoadhesive polymers can be ranked in the 
following order: SCMC>HPMC 100M>CbP934P. The amount of the 
mucoadhesive polymers had a non-significant effect. This was in a 
good correlation with patel et al. and Qadir et al. [13, 28]. They found 
that the tensile strength of the buccal patches increased with 
increasing the percentage of HPMC 15 cp. 
 
Table 2: Physico mechanical characterization of SCG patches.  
Formula code Thickness (mm) 
±SD 
Folding endurance Tensile strength (N/MM2)±SD % elongation 
±SD 
Weight variation±SD 
F1 0.210±0.006 >300 6.4±0.018 30.4±0.88 0.155±0.025 
F2 0.230±0.012 >300 7.5±0.053 39.5±0.71 0.155±0.015 
F3 0.235±0.015 >300 8.6±0.185 39.9±0.88 0.158±0.025 
F4 0.240±0.006 >300 10.5±0.172 43.5±0.55 0.160±0.009 
F5 0.250±0.006 >300 10.6±0.125 45.2±0.92 0.157±0.013 
F6 0.240±0.002 >300 11.6±0.006 47.9±0.75 0.160±0.015 
F7 0.250±0.015 >300 11.8±0.120 50.7±0.66 0.158±0.009 
F8 0.305±0.023 >300 12.6±0.080 51.5±0.68 0.175±0.009 
F9 0.320±0.012 >300 13.1±0.024 53.4±0.78 0.169±0.019 
F10 0.235±0.015 >300 9.8±0.085 43.2±0.88 0.155±0.011 
F11 0.250±0.006 >300 10.4±0.006 47.6±0.68 0.157±0.019 
F12 0.312±0.025 >300 11.2±0.085 49.1±0.92 0.170±0.015 
F13 0.355±0.012 >300 12.1±0.120 51.2±0.73 0.179±0.015 
*Data are expressed as mean±standard deviation of the mean (SD), n=3 
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Percent swelling  
Swelling of the polymer is an important property for the prolonged 
release of the drug and good mucoadhesion. Table 3 demonstrates 
the percent swelling of different patches. It is observed that there 
was an increase in the percent swelling with time. The obtained 
results revealed that the addition of mucoadhesive polymers 
increased the percent swelling of all prepared patches compared to 
CAB (F1) alone which had the lowest percent swelling. It is clear that 
SCMC had the highest percent swelling (F6-F9) followed by 
HPMC100M (F10-F13) and finally Cbp934P (F2-F5) that had a poor 
influence on the percent swelling. This could be ascribed to the 
presence of more hydroxyl group in SCMC compared to both 
HPMC100M and Cbp934P [35]. 
 
Table 3: Swelling percentages of SCG patches 
Formula code 5 (min) 10 (min) 15 (min) 20 (min) 30 (min) 60 (min) 
F1 3.7±0.006 5.2±0.01 8.6±0.08 10.2±0.09 15.6±0.82 20.8±0.99 
F2 4.8±0.006 6.2±0.01 10.7±0.05 13.5±0.06 18.6±0.54 24.9±1.5 
F3 4.8±0.009 7.8±0.008 11.8±0.01 14.6±0.08 19.7±0.35 25.9±0.85 
F4 5.6±0.08 9.2±0.006 12.6±0.009 15.8±0.01 19.6±0.85 24.6±1.9 
F5 4.5±0.06 8.9±0.01 13.2±0.08 16.7±0.009 20.1±0.96 26.2±0.58 
F6 3.5±0.006 9.4±0.008 16.8±0.08 23.1±0.06 25.5±0.54 35.5±0.85 
F7 2.8±0.008 8.6±0.006 17.2±0.009 27.1±0.09 32.5±0.96 40.4±1.5 
F8 3.5±0.006 10.6±0.08 19.2±0.006 28.6±0.09 35.2±0.87 45.4±1.9 
F9 2.8±0.01 8.2±0.08 18.6±0.009 26.8±0.04 35.4±0.58 53.2±1.5 
F10 2.6±0.008 5.8±0.006 10.2±0.08 14.2±0.08 18.2±0.99 31.5±0.85 
F11 3.1±0.006 7.2±0.008 13.8±0.06 15.6±0.09 19.8±0.96 35.4±0.96 
F12 3.5±0.01 7.8±0.06 14.5±0.06 16.8±0.04 20.5±1.5 39.4±0.54 
F13 2.8±0.01 9.4±0.08 15.7±0.009 18.2±0.04 21.2±1.5 41.5±0.85 
*Data are expressed as mean±standard deviation of the mean (SD), n=3 
 
Surface pH 
The surface pH of all prepared patches was found to be in the range 
from 6.4 to 6.9, which indicates that the prepared patches are non-
irritant to the buccal mucosa and expected to be palatable (table 4). 
Drug content 
Drug content of SCG buccal patches (2x2 cm) was observed to be in 
the range from 97.8±0.08 to 101.8±0.018 (table 4) which ensures 
homogeneous and uniform distribution of the drug throughout the 
prepared patches. 
Moisture uptake 
The moisture uptake of all prepared patches ranged from 3.2±0.08 
to 10.8±0.25 (table 4) which indicates that all prepared patches will 
remain stable and non-brittle with a poor chance of microbial attack 
[36]. It was found that the addition of mucoadhesive polymers 
increased the film hydrophilicity and resulted in a significant 
increase in moisture uptake [37]. Both HPMC 100M and SCMC 
increased moisture uptake more than Cbp934P compared to CAB 
alone (F1). The amount of mucoadhesive polymer had a non-
significant effect on moisture uptake of the prepared patches. 
Ex-vivo mucoadhesion strength 
Table 4 illustrated the results of mucoadhesion strength of all 
prepared patches. It is clear that patch which was prepared from 
CAB alone (F1) had the lowest mucoadhesion strength (17.2±0.014). 
The addition of mucoadhesive polymers increased the 
mucoadhesion significantly and their effect arranged in the following 
order SCMC>HPMC100M>CbP934P. It was observed that SCMC had 
the highest effect and Cbp934P had the lowest effect. Also, the 
results showed that the mucoadhesion behaviour is greatly 
influenced by the type of mucoadhesive polymer and increased with 
an increase in the concentration of hydrophilic polymer. The effect 
of SCMC could be attributed to the higher hydration and higher 
swelling. Shilpa et al. [38] found that buccal strips of pravastatin 
which were prepared from SCMC showed high mucoadhesion. Also, 
it was observed that HPMC had a lower effect on mucoadhesion 
compared to SCMC and this could be ascribed to the lack of proton 
donating carboxyl group which results in a decreased ability to form 
hydrogen bonds [39]. 
Ex-vivo mucoadhesion residence time 
Ex-vivo mucoadhesion residence time of all prepared patches is 
presented in table 4. It is obvious from the results that incorporation of 
both HPMC 100M and SCMC increased the residence time while 
Cbp934P had no effect compared to CAB alone (F1). It was found that 
as the amount of SCMC increased from 200 mg (F6) to 500 mg (F9), 
there was an increase in the residence time from 6.75±0.28 to 
8.3±0.25. The same behaviour was observed in case of HPMC 100M 
(F10-F13). The residence time of the prepared patches arranged as 
follows: SCMC>HPMC100M>CbP934P>CAB. From the obtained results 
of both percent swelling and mucoadhesion strength, it can be 
predicted that there was a good correlation between them, this means 
that patch with higher percent swelling had higher mucoadhesion and 
remain attached to the buccal mucosa for a longer time. 
 













F1 6.5±0.021 100.8±1.2 3.2±0.08 17.2±0.14 3.35±0.25 
F2 6.7±0.019 98.6±0.08 5.2±0.16 19.1±0.26 3.55±0.28 
F3 6.4±0.021 99.7±0.08 4.2±0.18 21.6±0.21 3.75±0.25 
F4 6.4±0.021 101.0±1.5 3.8±0.15 24.2±0.26 3.75±0.18 
F5 6.7±0.016 97.8±0.08 4.8±0.15 25.6±0.18 3.5±0.22 
F6 6.5±0.019 98.8±0.06 6.2±0.16 31.6±0.25 6.75±0.28 
F7 6.4±0.015 99.5±1.6 8.1±0.18 37.6±0.18 7.15±0.18 
F8 6.5±0.012 99.2±0.08 9.8±0.19 41.1±0.15 7.45±0.28 
F9 6.8±0.015 98.2±0.18 10.8±0.25 51.2±0.26 8.3±0.25 
F10 6.8±0.015 99.4±1.8 6.3±0.25 23.2±0.18 4.5±0.21 
F11 6.8±0.012 101.2±1.7 7.2±0.21 25.1±0.11 4.7±0.18 
F12 6.8±0.019 99.8±1.9 9.1±0.28 28.5±0.22 5.7±0.15 
F13 6.6±0.011 101.8±0.018 10.4±0.21 30.2±0.17 6.7±0.25 
*Data are expressed as mean±standard deviation of the mean (SD), n=3 
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In vitro release study 
In vitro release studies were performed in phosphate buffer pH 6.8 to 
simulate buccal cavity. The release profiles of the prepared patches are 
clearly illustrated in figs. (1-3). It is obvious from the figs. that 95.2±1.4 
% of the incorporated dose released from F1 after 8 h. The addition of 
Cbp934P had non-significant effect at low concentration as observed 
in F2 (92.4±1.5) and F3 (90.1±0.8) but upon increasing its 
concentration there was a slight but significant reduction in the 
amount of drug released after 8 h, as observed in F4 (89.1±1.3) and F5 
(87.2±1.5) (fig. 1). It is clear from fig. 2 that incorporation of SCMC 
significantly retarded the release of SCG from F7 (87.1±0.8), F8 
(82.1±1.5) and F9 (75.2±1.1) after 8 h. Similar behaviour was 
observed with HPMC100M (fig. 3). From the previous, it can be 
concluded that the mucoadhesive polymers retarded the release in the 
following order SCMC>HPMC100M>CbP934P. The retarding effect of 
SCMC and HPMC100M could be attributed to the fact that upon contact 
of both polymers with the dissolution medium, they undergo swelling 
forming a thick gel layer on the surface of the swollen patch which lead 
to an increase in the diffusional path length [40, 41] in addition to the 
prevention of the matrix disintegration by retarding penetration of the 
dissolution medium into the patch [42]. Magdy et al. found that 
montelukast released slowly from patches which were prepared from 
either SCMC or HPMC [14], Also, Mishra et al. found that incorporation 




Fig. 1: Cumulative drug release percent of SCG from CAB±CbP934P 
different patches, n=3±SDM (standard deviation of the mean) 
 
 
Fig. 2: Cumulative drug release percent of SCG from CAB±SCMC 
different patches, n=3±SD 
 
 
Fig. 3: Cumulative drug release percent of SCG from CAB±HPMC 
different patches, n=3±SD 
Kinetic data analysis 
The in vitro release profile of all prepared mucoadhesive patches 
follow Higuchi diffusion model. 
Ex-vivo drug permeation study 
F5, F9 and F13 were selected for ex-vivo permeation through the 
porcine buccal mucosa based on their physicomechanical characters, 
release profiles and the used mucoadhesive polymer. It was found 
that 82.1±1.7, 70.1±0.8 and 75.6±1.5 of the incorporated dose were 
permeated through the porcine buccal mucosa from F5, F9 and F13 
respectively (fig.4). By comparing the release profile and permeation 
profile of each formula, it can be concluded that there was a good 
correlation between the release and permeation of SCG which gives 
a good evidence for the effective therapeutic response of the 
prepared patches. Mehraj udin et al. found that there was a good 
correlation between in vitro release data and ex-vivo permeation 
data of methyldopa from HPMC K47-PVP K30 patches [18]. 
 
 
Fig. 4: Cumulative drug release percent of SCG permeated 
through the porcine buccal mucosa, n=3±SDM 
 
In vivo pharmacokinetic study 
Fig.5 shows the chromatogram of the rabbit plasma of SCG. It can be 
observed that well-resolved peak obtained at 5.4 min for SCG. Fig.6 
represents the plasma profile of SCG optimized patch (F9) and 
parenteral solution as a function of time. It is clearly observed that 
there was a significant difference in the mean plasma concentration 
of both parenteral solution and mucoadhesive patch at all-time 
intervals. Table 5 depicts the mean pharmacokinetic parameters of 
tested formulae. From the illustrated results, it can be noticed that 
after administration of parenteral solution of SCG the peak plasma 
concentration was14.2±1.2 µg/h/ml and reached rapidly after 
1.15±0.06 h, whereas peak plasma concentration of mucoadhesive 
patch was 9.9±0.08 µg/h/ml and reached after 3.85±0.008 h. The 
increase in Tmax and the decrease in Cmax of SCG patch compared to 




Fig. 5: Typical HPLC chromatogram of SCG in rabbit plasma
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Table 5: Pharmacokinetic parameters of SCG patch and parenteral solution 
Formula  Cmax (µg/h/ml)±SD* Tmax (h)±SD AUC0-24±SD 
SCG patch (F9) 9.9±0.08 3.85±0.008 10.76±0.85 
Parenteral solution 14.2±1.2 1.15±0.06 10.12±0.56 
*All results are expressed as the mean of six determinations±standard deviations of the mean (SD) 
 
 
Fig. 6: Mean plasma levels of SCG of the parenteral solution and optimized mucoadhesive buccal patch F9, Sample size= 6±SD 
 
CONCLUSION 
From the previous results it can be concluded that mucoadhesive 
buccal patches which were prepared from cellulose acetate butyrate 
and carboxy methyl cellulose sodium (F9) showed a good in vitro 
characteristics, an enhanced bioavailability and considered a 
promising dosage form to solve the poor oral absorption and short 
half-life of the drug.  
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